The Growing Demand For NASH Treatment Amid Obesity Epidemic: Transformative Forces Shaping the Non-Alcoholic Steatohepatitis (NASH) Market Landscape in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Recent years have witnessed a remarkable expansion in the size of the non-alcoholic steatohepatitis (NASH) market. It is projected to escalate from $4.5 billion in 2024 to $6.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 36.1%. The previous growth can be accredited to an increased occurrence of NASH, obesity outbreak, growing consciousness and diagnosis, changes in lifestyle and diet regimes, along with the development of healare infrastructure.

Non-Alcoholic Steatohepatitis (NASH) Market Size Forecast: What's the Projected Valuation by 2029?
The market for non-alcoholic steatohepatitis (NASH) is projected to witness substantial growth in the coming years, with expectations to reach $19.07 billion in 2029, recording a compound annual growth rate (CAGR) of 32.8%. This anticipated growth during the forecast period can be credited to the progress in NASH drug development, the rise in NASH screening initiatives, expansion in healare spending, joint research endeavors, and supportive government regulations and endorsements. The forecast period is expected to be characterized by an emphasis on lifestyle changes and patient awareness, enhanced cooperation in clinical studies, advancements in regulations and pathway designations, and the incorporation of artificial intelligence in diagnosis and monitoring procedures.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

What Are the Drivers Transforming the Non-Alcoholic Steatohepatitis (NASH) Market?
The escalating instances of obesity are propelling the demand for the non-alcoholic steatohepatitis (NASH) market. Obesity, characterized by uncontrolled or excessive fat accumulation, poses a health threat and indicates a body weight exceeding the healthy benchmark for an individual of a certain height. With the obesity epidemic contributing to a higher prevalence of non-alcoholic fatty liver disease, NASH could potentially become the leading cause of critical liver disease in the upcoming decades. This in turn intensifies the requirement for NASH treatments and associated drugs. For example, as per the World Health Organization (WHO), a UK-based global public health institution, it was observed in March 2024 that around 2.5 billion adults over the age of 18 were regarded as overweight in 2022, with 890 million among them grappling with obesity. Therefore, the growing incidence of obesity is anticipated to fuel the expansion of the non-alcoholic steatohepatitis (NASH) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

What Long-Term Trends Will Define the Future of the Non-Alcoholic Steatohepatitis (NASH) Market?
Top-tier firms in the non-alcoholic steatohepatitis (NASH) market are innovating thyroid hormone receptor-beta (THR-beta) agonists to optimize liver metabolism, mitigate the gathering of liver fat, and heighten liver efficacy. These THR-beta agonists are exceptional substances that selectively trigger the thyroid hormone receptor-beta variant, a core receptor in supervising metabolism, proliferation, and evolution. For example, the US-regulated body, Food and Drug Administration, sanctioned Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, in March 2024. It was recognized as the primary treatment for noncirrhotic NASH in adults with moderate to severe liver scarring (fibrosis). By selectively spurring the THR-beta receptor, Rezdiffra aids in managing lipid metabolism, resulting in lessening of intrahepatic triglycerides and total liver fat accumulation.

Which Segments in the Non-Alcoholic Steatohepatitis (NASH) Market Offer the Most Profit Potential?
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented -

1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral

Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=8805&type=smp

Which Firms Dominate the Non-Alcoholic Steatohepatitis (NASH) Market by Market Share and Revenue in 2025?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Which Regions Offer the Highest Growth Potential in the Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.